14 research outputs found
copanlisib monotherapy activity in relapsed or refractory indolent b cell lymphoma combined analysis from phase i and ii studies
Get PDFn/
Arterial thrombosis associated with anticardiolipin and anti-β2-glycoprotein-Iantibodies in patients with non-Hodgkin's lymphoma: a report of two cases
No full textPrevalence and clinical significance of anticardiolipin and anti-β2-glycoprotein-I antibodies in patients with non-Hodgkin's lymphoma
No full textPhase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
No full textResolution of psoriatic skin lesions after chemotherapy with gemcitabine and vinorelbine
No full textPharmacokinetic and pharmacodynamic relationships of copanlisib in patients with non-Hodgkin lymphoma and advanced solid tumors
No full textEvaluation of Significance of Lymphocyte Subpopulations and Non-specific Serologic Markers in B-cell Non-Hodgkin’s Lymphoma Patients
No full textAntiphospholipid Antibodies Are Not Associated with Clinical Parameters or Prognostic Outcomes in Patients with Non-Hodgkin's Lymphoma
No full text
